Table 1 Clinical data of 35 patients with lymphoma complicated with primary solid tumor
From: Clinical analysis of lymphoma with malignant solid tumor simultaneously: a retrospective case series
No. | Sex/ age | Lymphoma | Â | Solid tumor | 1st Tumor | Survival Status | Follow-up (month) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Subtypes | site | Treatment | Â | Subtypes | site | Treatment | |||||
1 | M/49 | MALT | Parotid gland | RT | Â | Papillary carcinoma | Thyroid | Surgery | Lymphoma | Survival | 38 |
2 | M/69 | SLL/CLL | Lymph node | No treatment | Â | Clear cell carcinoma | Kidney | Surgery and Axitinib | Lymphoma | Survival | 34 |
3 | F/59 | DLBCL | Sinuses | RCDOP, RCHOP, RTX, MTX, and autoHSCT | Â | Papillary carcinoma | Thyroid | Levothyroxine sodium | Lymphoma | Survival | 33 |
4 | M/76 | DLBCL | Abdominal cavity | No treatment | Â | Adenocarcinoma | rectum | No treatment | Solid tumor | Death | 3 |
5 | F/66 | DLBCL | Pelvic cavity | RCHOP and RCDOP | Â | Papillary carcinoma | Thyroid | NA | Lymphoma | NA | NA |
6 | F/55 | DLBCL | Lymph node | RCHOP, RCDOP and RGDP | Â | Papillary carcinoma | Thyroid | Surgery | Solid tumor | NA | NA |
7 | M/74 | DLBCL | Small intestine | Refusal of treatment | Â | Adenocarcinoma | Stomach | Surgery | Lymphoma | Death | 6 |
8 | F/81 | DLBCL | Pharynx | RminiCHOP and RminiCDOP | Â | Papillary carcinoma | Thyroid | No treatment | Lymphoma | Survival | 28 |
9 | F/70 | MALT | Breast | Mammotome excision | Â | Invasive ductal carcinoma | Breast | Surgery, EPI, CTX, DTX and RT | Lymphoma | Survival | 27 |
10 | M/80 | PTCL | Skin | miniCVP and miniCHOP | Â | Adenocarcinoma | Prostate | Endocrine therapy | Lymphoma | Survival | 27 |
11 | M/70 | MZL | Lymph node | RCDOP, CVP and Obrutinib | Â | Adenocarcinoma | Prostate | Endocrine therapy | Lymphoma | Survival | 27 |
12 | M/62 | SLL/CLL | Appendix | Surgery and Ibrutinib | Â | Adenocarcinoma | Lung | Surgery | Solid tumor | Survival | 26 |
13 | F/72 | FL | tonsil | RCHOP | Â | Adenocarcinoma | Lung | Surgery | Lymphoma | Survival | 24 |
14 | M/74 | SLL/CLL | Abdominal cavity | No treatment | Â | Adenocarcinoma | Colon | Surgery | Solid tumor | Survival | 23 |
15 | F/67 | DLBCL | Stomach | RCDOP | Â | Papillary carcinoma | Thyroid | No treatment | Lymphoma | Survival | 19 |
16 | F/83 | DLBCL | Stomach | R-miniCDOP, R2-GemOx and BR | Â | Adenocarcinoma | Rectum | No treatment | Lymphoma | Death | 6 |
17 | M/57 | FL | Lymph node | RCHOP | Â | Squamous cell carcinoma | Lung | Microwave ablation | Lymphoma | Survival | 17 |
18 | F/55 | SLL/CLL | Lymph node | Ibrutinib and RTX | Â | Micropapillary carcinoma | Thyroid | Surgery | Lymphoma | Survival | 68 |
19 | M/68 | PTCL | Small intestine | CHOP | Â | Papillary urothelial carcinoma | Bladder | Transurethral resection of bladder tumors | Solid tumor | NA | NA |
20 | M/75 | DLBCL | Lymph node | R2-GemOx | Â | Adenocarcinoma | Colon | No treatment | Solid tumor | Death | 1 |
21 | F/55 | MALT | Stomach | RT and RCVP | Â | Papillary carcinoma | Thyroid | Surgery | Lymphoma | Survival | 56 |
22 | M/65 | DLBCL | Stomach | miniCHOP and RCHOP | Â | Adenocarcinoma | appendix | Surgery | Solid tumor | Death | 6 |
23 | M/80 | SLL/CLL | Lymph node | No treatment | Â | Adenocarcinoma | Stomach | Surgery | Lymphoma | NA | NA |
24 | M/72 | SLL/CLL | Lymph node | No treatment | Â | Adenocarcinoma | Lung | Cisplatin and Pemetrexed | Lymphoma | Death | 20 |
25 | M/68 | MZL | Lymph node | No treatment | Â | Adenocarcinoma | Stomach | Surgery and SOX | Lymphoma | Survival | 41 |
26 | M/62 | MZL | Lymph node | NA | Â | Squamous cell carcinoma | Pharynx | Surgery, RT and chemotherapy | Lymphoma | NA | NA |
27 | M/71 | DLBCL | Ileocecal | RCHOP | Â | Adenocarcinoma | Colon | No treatment | Lymphoma | Survival | 16 |
28 | M/59 | DLBCL | Lymph node | RCHOP and PD1 + RICE |  | Adenocarcinoma | Stomach | Surgery | Lymphoma | Survival | 15 |
29 | M/62 | DLBCL | Tonsil | RCDOP | Â | Adenocarcinoma | Stomach | Surgery | Solid tumor | Survival | 14 |
30 | M/79 | SLL/CLL | Rectum | Surgery | Â | Adenocarcinoma | Rectum | Surgery | lymphoma | Survival | 14 |
31 | F/66 | SLL/CLL | Lymph node | No treatment | Â | Adenocarcinoma | Lung | Targeted therapy | Solid tumor | Survival | 7 |
32 | M/59 | PTCL | Lymph node | Chemotherapy | Â | NA | Lung | Surgery | lymphoma | Survival | 10 |
33 | M/65 | WM | bone marrow | Obrutinib | Â | Adenocarcinoma | Colon | Surgery | Solid tumor | Survival | 7 |
34 | F/67 | MZBL | Lymph node | BR | Â | Papillary carcinoma | Thyroid | No treatment | Lymphoma | Survival | 1 |
35 | F /65 | DLBCL | Lymph node | RCHOP | Â | Adenocarcinoma | Lung | No treatment | lymphoma | Survival | 0 |